Sabra Health Care price target raised to $15 from $13 at Truist

Truist raised the firm’s price target on Sabra Health Care to $15 from $13 and keeps a Buy rating on the shares. The stock still trades at a relatively undemanding valuation, and there could be continued upside as the senior housing operating portfolio recovers and the company likely returns to positive earnings growth in 2024 with no near-term debt maturities to contend with, the analyst tells investors in a research note.